全文获取类型
收费全文 | 4779篇 |
免费 | 541篇 |
国内免费 | 235篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 7篇 |
妇产科学 | 3篇 |
基础医学 | 73篇 |
口腔科学 | 6篇 |
临床医学 | 133篇 |
内科学 | 489篇 |
皮肤病学 | 16篇 |
神经病学 | 21篇 |
特种医学 | 74篇 |
外科学 | 124篇 |
综合类 | 1149篇 |
预防医学 | 77篇 |
眼科学 | 28篇 |
药学 | 783篇 |
1篇 | |
中国医学 | 2545篇 |
肿瘤学 | 23篇 |
出版年
2024年 | 23篇 |
2023年 | 81篇 |
2022年 | 135篇 |
2021年 | 211篇 |
2020年 | 210篇 |
2019年 | 121篇 |
2018年 | 110篇 |
2017年 | 150篇 |
2016年 | 173篇 |
2015年 | 162篇 |
2014年 | 399篇 |
2013年 | 356篇 |
2012年 | 494篇 |
2011年 | 421篇 |
2010年 | 346篇 |
2009年 | 262篇 |
2008年 | 291篇 |
2007年 | 300篇 |
2006年 | 286篇 |
2005年 | 226篇 |
2004年 | 163篇 |
2003年 | 168篇 |
2002年 | 108篇 |
2001年 | 95篇 |
2000年 | 68篇 |
1999年 | 54篇 |
1998年 | 46篇 |
1997年 | 25篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 10篇 |
1993年 | 6篇 |
1992年 | 8篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1982年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有5555条查询结果,搜索用时 31 毫秒
91.
目的探讨胆闭通络方对幼鼠阻塞性黄疸FPA及D-二聚体(D-D)影响。方法将SD大鼠幼鼠分为3组,第1组为正常对照组,予生理盐水灌胃,第2组为模型组,采用2%α-萘异硫氰酸酯(ANIT)及生理盐水灌胃,第3组为治疗组,在造模同时予胆闭通络方灌胃,每日1次,连续7d。以分光光度仪检测血清丙氨酸氨基转移酶(ALT)、天门冬氨酶氨基转移酶(AST)、碱性磷酸酶(AKP)、γ-谷氨酰转肽酶(γ-GT)、血清总胆红素(TB)含量;双抗体夹心法测定大鼠血清血纤肽/纤维蛋白肽A(FPA)及D-D水平。结果与模型组比较,治疗组血清TB、ALT、AST、AKP、r-GT降低(P0.05);与对照组比较,模型组及治疗组血清FPA及D-D显著增高(P0.05);与模型组比较,治疗组血清FPA及D-D降低(P0.05)。结论胆闭通络方能抑制FPA及D-D产生,减少肝内微血栓的形成,缓解肝脏瘀血。 相似文献
92.
海珠益肝胶囊对小鼠免疫性肝损伤的影响 总被引:2,自引:0,他引:2
目的:进一步证实海珠益肝胶囊对肝损伤小鼠的保肝降酶作用。方法:来用卡介苗 脂多糖(BCG LPS)造成免疫性肝损伤模型小鼠,观察本品对血清中ALT、AST活力单位、肝脾脏器系数和肝脏病理组织学损伤程度的影响。结果:药物能降低血清中ALT、AST活力单位(P<0.01);减小肝脾肿大及脏器系数(P<0.01);减轻肝组织病理损伤程度。结论:海珠益肝胶囊对BCG LPS所致肝损伤小鼠有明显保肝降酶作用。 相似文献
93.
《Gastroenterologia y hepatologia》2021,44(10):696-703
IntroductionSmall bowel capsule endoscopy (SBCE) is a non-invasive diagnostic technique whose use in inflammatory bowel disease (IBD) has spread. A panenteric capsule, PillCam Crohn's (PCC), has recently been developed. We lack information on the availability and use of the CEID and PCC in our environment.MethodsWe conducted an electronic and anonymous survey among the members of the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) [Spanish Working Group on Crohn's Disease and Ulcerative Colitis] and the Asociación Española de Gastroenterología (AEG) [Spanish Association of Gastroenterology], consisting of 37 multiple-choice questions.ResultsOne hundred and fifty members participated, the majority dedicated to IBD (69.3%). 72.8% worked at centres with an IBD unit. 79% had SBCE available at their hospital, 14% referred patients to another centre; 22% had a PCC available, 9% referred patients to another centre. 79.3% of respondents with available SBCE used it in a small percentage of patients with IBD and 15.6% in the majority. The most frequent scenarios were suspicion of Crohn's disease (76.3%), assessment of inflammatory activity (54.7%) and assessment of the extent of the disease (54.7%). More than half (59.7%) preferentially used the Patency capsule to assess intestinal patency. Almost all respondents (99.3%) considered that training resources should be implemented in this technique.ConclusionsSBCE is widely available in Spanish hospitals for the management of IBD, although its use is still limited. There is an opportunity to increase training in this technique, and consequently its use. 相似文献
94.
G. Blanco-Velasco R. Palos-Cuellar M.R. Domínguez-García O.M. Solórzano-Pineda R.A. Zamarripa-Mottú C. Martínez-Camacho M.L. González-Bautista M.M. Contreras Serratos E. Murcio-Pérez J.M. Blancas-Valencia M.A. Jiménez-Ochoa O.V. Hernández-Mondragón 《Revista de gastroenterologia de Mexico》2021,86(3):215-219
Introduction and aimGraft-versus-host disease (GvHD) is a complication of hematopoietic cell transplantation, and the small bowel is one of the main targets in the gastrointestinal tract. Capsule endoscopy is a safe procedure and can be useful in the diagnosis of GvHD. The aim of the present study was to compare the diagnostic yield of capsule endoscopy with the histopathologic findings in GvHD.Materials and methodsA retrospective diagnostic test study included all the patients with suspected GvHD that underwent gastroscopy and colonoscopy, with histopathologic evaluation of the biopsies taken, and capsule endoscopy, within the time frame of July 2015 and July 2019. Capsule endoscopy findings were compared with the histopathologic diagnosis, considered the gold standard.ResultsTwenty-one patients with GvHD (7 [33%] women; 37 ± 11.9 years of age) were included, 20 (95%) of whom had acute GvHD. The median gastric transit time of the capsule was 55 minutes (20-113) and the median small bowel transit time was 261 minutes (238-434). The entire small bowel was visualized through capsule endoscopy in 17 cases (80.95%). The histopathologic findings and capsule endoscopy findings resulted in the diagnosis of GvHD in 17 and 16 cases, respectively. There was agreement between the histopathologic and capsule endoscopy findings in 18 cases (15 positive and 3 negative). Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic yield of capsule endoscopy were 88%, 75%, 94%, 60%, and 85%, respectively.ConclusionsCapsule endoscopy is a safe tool for the diagnosis of GvHD, with high sensitivity and positive predictive value, as well as moderate agreement with histopathologic findings. 相似文献
95.
【目的】探讨益气活血通络法治疗冠心病的疗效以及对血管内皮功能、免疫调节的影响。【方法】将82例冠心病患者随机分为治疗组和对照组各41例,对照组给予常规西药治疗,治疗组在对照组基础上加服益气活血通络方,比较2组心绞痛疗效、心电图疗效和临床症状疗效,观察2组治疗前后血浆血管内皮生长因子(VEGF)、内皮素-1(ET-1)及超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)等指标的变化情况。【结果】(1)治疗后,2组心绞痛疗效及心电图疗效比较,差异无统计学意义(P>0.05);临床症状疗效方面,治疗组优于对照组(P<0.05)。(2)治疗后,治疗组VEGF含量显著升高,ET-1含量显著下降(P<0.01);对照组治疗前后VEGF、ET-1含量比较,差异均无统计学意义(P>0.05);治疗组在改善VEGF、ET-1含量方面均显著优于对照组(P<0.01)。(3)治疗后,治疗组hs-CRP、IL-1β含量均显著下降(P<0.01);对照组hs-CRP、IL-1β含量均有下降趋势,但差异均无统计学意义(P>0.05);治疗组在改善hs-CRP、IL-1β含量方面均显著优于对照组(P<0.01)。【结论】对冠心病心绞痛患者,在常规西药治疗的基础上加用益气活血通络法治疗,能更好地达到缓解心绞痛、改善临床症状的目的,这可能与其改善血管内皮功能和免疫调节功能等有关。 相似文献
96.
Objective:To confirm the efficacy and safety of Wufuxinnaoqing Soft Capsule(五福心脑清胶囊,WSC)in the treatment of chronic stable angina(blood stasis syndrome).Methods:A multicenter,randomized,double-blind,placebo-controlled trial with superiority test was designed.A total of 240 patients with chronic stable angina(blood stasis syndrome)from multiple centers were randomly and equally assigned to the treatment group and the control group.Based on standard treatment of Westem medicine,the treatment group was given WSC,while the control group was given WSC mimetic,both for 12 weeks.Observed indicators included the efficacy in angina,the efficacy in Chinese medicine syndrome,the withdrawal or reduce rate of nitroglycerin and routine safety indices.Results:After 12-week treatment,the significant effective rate and total effective rate of the treatment group were significantly better than those of the control group(23.5%vs.9.2%,64.7%vs.30.8%),respectively,with statistically significant difference(P0.01).After 12-week treatment,the decreased points and the decreased rate of angina symptom score in the treatment group were better than in the control group(5.1±4.2 points vs.2.8±3.5 points,44.9%±37.2%vs.25.4%±30.7%)respectively,with significant difference(P0.01).After 12-week treatment,the significant effective rate and total effective rate of the treatment group were better than the control group(respectively,30.3%vs.15.0%,67.2%vs.45.0%,P0.01).After 8-or 12-week treatment,the decreased points and the decreased rate of Chinese medicine syndrome score in the treatment group were better than the control group(P0.05 or P0.01).After 12-week treatment,nitroglycerin withdrawal rate and the withdrawal or reduce rate in treatment group were better than the control group(P0.01).On safety evaluation,the incidence of adverse events(7.563%vs.7.500%)and the incidence of cardiovascular events(0.840%vs.0.000%)in the treatment group were similar with the control group,and the difference was not statistically significant(P0.05).Conclusion:In treatment of chronic stable angina(blood stasis syndrome),WSC can reduce angina attacks and consumption of nitroglycerin,decrease angina severity degree,effectively relieve the blood stasis syndromes,such as chest pain,chest tightness,palpitations,dark purple tongue and other symptoms.Besides,adverse events and cardiovascular adverse events in the treatment group and the control group showed no difference.All shows that the drug is safe and effective.[This study was registered in Chinese Clinical Trial Registry(ChiCTR),with registration number:ChiCTR-TRC-14005158.] 相似文献
97.
目的:观察异维A酸胶丸联合红霉素肠溶胶囊治疗难治性痤疮的效果。方法:将106例难治性痤疮患者随机均分成两组,治疗组给予异维A酸胶丸联合红霉素肠溶胶囊,对照组给予异维A酸胶丸治疗4周,观察用药后两组临床指标的改善情况。结果:治疗组与对照组总有效率分别为86.79%、67.92%(P<0.05),临床疗效治疗组优于对照组。结论:异维A酸胶丸联合红霉素肠溶胶囊治疗难治性痤疮安全、有效。 相似文献
98.
胶囊内镜对小肠疾病的诊断价值分析 总被引:26,自引:5,他引:26
目的 了解胶囊内镜检查在国人运用的临床特性,评价胶囊内镜对国人小肠疾病的诊断价值。方法 分析55例次胶囊内镜检查的临床资料。结果 (1)53例受检者进行了55次胶囊内镜检查,成功54次,成功率为98.2%。53例受检者均耐受了检查,未出现并发症。(2)胶囊内镜在胃内滞留平均时间为44min(6—135min),小肠内滞留平均时间为334min(90—433mim)。在检查记录有效期间,胶囊内镜顺利通过回盲瓣42例,未通过12例。52例胶囊在检查结束后顺利排出体外,排出平均时间为24h(5h 10min~72h)。(3)检出了小肠癌、淋巴瘤、息肉、平滑肌瘤、黄色瘤、克罗恩病、非特异性炎症、蛔虫症、鞭虫症、异物及血管畸形等。结论 胶囊内镜检查操作简单、安全、有效,检查成功率高,对小肠黏膜、血管及黏膜下等病变的检出能力较小肠钡剂灌肠、血管造影为高,具有较好的诊断价值。胶囊内镜的最大缺点是观察不能重复,不能获得组织学诊断和较为准确的定位诊断。 相似文献
99.
目的观察自行研制的中药双甲五灵胶囊治疗慢性肝炎患者前后血清基质金属蛋白酶组织抑制剂1(TIMP1)的变化及意义,并观察双甲五灵胶囊治疗的临床疗效。方法将226例慢性肝炎患者随机分为双甲五灵胶囊治疗组和对照组,观察两组治疗半年前后临床症状、体征、肝功能、血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)、层粘连蛋白(LN)以及TIMP1的变化,并进行统计学处理。结果双甲五灵胶囊治疗组与对照组比较,治疗组患者临床症状、体征、肝功能及血清肝纤维化指标明显好转(P<0.01)。结论双甲五灵胶囊可使患者血清中TIMP1水平明显降低,用于防治肝纤维化有效。双甲五灵胶囊对防治慢性肝炎肝纤维化有一定效果。 相似文献
100.